United Therapeutics Corporation (UTHR)
UTHR · Health Care · 
United States
United Therapeutics Corporation (UTHR) is a US company in the Health Care sector. The stock has its largest weight in XUHL (MSCI USA Health Care), at 0.34%. Anyone who holds an ETF containing United Therapeutics Corporation also has an indirect stake in the company.
Data and Charts: United Therapeutics Corporation
Key Data for United Therapeutics Corporation
United Therapeutics Corporation Stock Price Chart
The United Therapeutics Corporation chart shows daily closing prices and is set to the current year by default. The stock is up 22.9% year to date and up 32.0% over twelve months. The last recorded close on October 30, 2026, was $598.72, at 100% of the 52-week range.
Price series from our database since Aug 12, 2024, 558 daily values.
United Therapeutics Corporation Stock Performance
| Year to date | +22.9% | 1 year | +32.0% |
|---|---|---|---|
| 1 month | +10.5% | 3 months | +15.6% |
| Calendar year 2025 | +38.1% |
Measured in euros, United Therapeutics Corporation is up 29.2% year to date and up 36.5% over twelve months. The difference from the dollar figures above comes from the exchange rate alone. Each daily price is converted at the ECB euro reference rate for that day.
Alysly Data Analysis: United Therapeutics Corporation
What ETF Is United Therapeutics Corporation In?
United Therapeutics Corporation has above-average ETF coverage and is held by 20 of the 104 ETFs we track, which together follow 11 indices. That puts the stock in more ETFs than 81.7% of the 4,341 stocks we track.
| ETF | Index | Weight | per €1,000 in the ETF |
|---|---|---|---|
| XUHL / XUHC | MSCI USA Health Care | 0.34% | €3.39 |
| SPFS | MSCI World Health Care | 0.25% | €2.51 |
| XDWH | MSCI World Health Care | 0.25% | €2.50 |
| XDEB | MSCI World Minimum Volatility | 0.17% | €1.68 |
| XDEM | MSCI World Momentum | 0.08% | €0.78 |
| WVAL | MSCI World Value | 0.07% | €0.72 |
| XDEQ | MSCI World Quality | 0.04% | €0.40 |
| XD9U / XD9D | MSCI USA | 0.03% | €0.34 |
| SWWD | MSCI World | 0.03% | €0.31 |
| SPPW | MSCI World | 0.03% | €0.31 |
| EUNL | MSCI World | 0.03% | €0.30 |
| IUSQ | MSCI ACWI | 0.03% | €0.30 |
| XDWD / XDWL | MSCI World | 0.02% | €0.25 |
| SPYY | MSCI ACWI | 0.02% | €0.22 |
| WIMI | MSCI World IMI | 0.01% | €0.13 |
| SPYI / SPSA | MSCI ACWI IMI | 0.01% | €0.05 |
The last column shows how much of €1,000 in one of these funds goes to United Therapeutics Corporation, based on each fund's latest holdings list.
US-listed ETFs holding United Therapeutics Corporation (weight per latest SEC filing): ONEQ 0.05%, VTI 0.03%. These funds are registered in the US; retail investors in the EU usually cannot buy them.
United Therapeutics Corporation Weight in iShares Core MSCI World (EUNL) Since 2023
In iShares Core MSCI World (EUNL), United Therapeutics Corporation had a weight of 0.02% on Mar 31, 2023 and 0.03% on Oct 30, 2026. The fund tracks the MSCI World. Its share peaked at 0.03% on Dec 31, 2025. The weight rises and falls with the stock's price performance relative to the other index members. It can also change when the index provider adjusts the index composition.
What's Inside Your ETF Portfolio and the ETF overlap check show how much United Therapeutics Corporation overlaps with the rest of a portfolio.
Which Tracked Investors Hold United Therapeutics Corporation?
United Therapeutics Corporation is not among the largest purchases in the quarter ending Jun 30, 2026. The list is led by GOOGL, DAL and NEBIUS GROUP N.V. The only manager we track that holds United Therapeutics Corporation increased its position.
| Investor | Shares | Value | Quarter |
|---|---|---|---|
| Bridgewater Associates | 111,326 | $60M | increased by 157 |
As of Jun 30, 2026. Based on quarterly filings with the US securities regulator, submitted up to 45 days after the reference date. The change counts shares, not price gains.
What United Therapeutics Corporation Executives and Directors Traded Recently
| Date | Person | Type | Shares | Price |
|---|---|---|---|---|
| Oct 29, 2026 | ROTHBLATT MARTINE A Director, Officer, Chairperson & CEO | Sell (plan) | 40 | $599.30 |
| Oct 29, 2026 | ROTHBLATT MARTINE A Director, Officer, Chairperson & CEO | Sell (plan) | 919 | $597.66 |
| Oct 29, 2026 | ROTHBLATT MARTINE A Director, Officer, Chairperson & CEO | Sell (plan) | 1,355 | $596.86 |
| Oct 29, 2026 | ROTHBLATT MARTINE A Director, Officer, Chairperson & CEO | Sell (plan) | 1,678 | $595.88 |
| Oct 29, 2026 | ROTHBLATT MARTINE A Director, Officer, Chairperson & CEO | Sell (plan) | 1,248 | $594.89 |
| Oct 29, 2026 | ROTHBLATT MARTINE A Director, Officer, Chairperson & CEO | Sell (plan) | 1,540 | $593.88 |
| Oct 29, 2026 | ROTHBLATT MARTINE A Director, Officer, Chairperson & CEO | Sell (plan) | 1,563 | $592.97 |
| Oct 29, 2026 | ROTHBLATT MARTINE A Director, Officer, Chairperson & CEO | Sell (plan) | 1,104 | $591.90 |
The table shows open-market purchases and sales reported over the past 90 days. Directors, officers and shareholders owning more than ten percent must report such transactions within two trading days. Awards and option exercises are excluded.
“Plan” means the transaction follows a schedule set up in advance under Rule 10b5-1. Sales consistently outnumber purchases in these filings because a large part of executive pay is granted in shares. For comparison: over the period covered, executives and directors reported sales at 271 of 350 tracked companies and purchases at 32.
Stocks With ETF Exposure Similar to United Therapeutics Corporation
| Stock | Shared ETFs | r | 1 year | Annualized volatility | Net margin | Revenue growth |
|---|---|---|---|---|---|---|
| United Therapeutics Corporation | – | – | +32.0% | 41.2% | 41.9% | +10.6% |
| Neurocrine Biosciences | 17 | +0.31 | +5.8% | 36.2% | 16.7% | +21.4% |
 Roivant Sciences | 17 | +0.30 | +88.5% | 39.4% | -3,629.2% | -71.6% |
 Revolution Medicines | 17 | – | +225.0% | 56.2% | – | – |
 Royalty Pharma Plc | 18 | – | +81.9% | 23.4% | 32.4% | +5.1% |
 Insmed Incorporated | 16 | – | -42.0% | 54.9% | -210.5% | +66.7% |
 Medline | 16 | – | – | 43.8% | 4.1% | +11.5% |
 Natera | 16 | – | +114.4% | 46.7% | -9.0% | +35.9% |
 Johnson & Johnson | 19 | – | +44.5% | 19.6% | 28.5% | +6.0% |
These stocks reach a portfolio through largely the same funds as United Therapeutics Corporation. “Shared ETFs” counts the funds that hold both.
Return and volatility are calculated from our daily closing prices in US dollars. Margin and growth come from each company's latest SEC annual filing. Because fiscal years do not end on the same date for every company, the underlying periods are not fully identical.
Fundamental Analysis: United Therapeutics Corporation
United Therapeutics Corporation Key Financials
Figures come from the SEC annual filing for the latest reported fiscal year (period end Dec 31, 2025).
| Fiscal year | Revenue | Net income | Margin |
|---|---|---|---|
| FY ended Dec 2023 | 2.3 | 1.0 | 42.3% |
| FY ended Dec 2024 | 2.9 | 1.2 | 41.5% |
| FY ended Dec 2025 | 3.2 | 1.3 | 41.9% |
Technical Analysis: United Therapeutics Corporation
United Therapeutics Corporation Risk Metrics
The close on Oct 30, 2026, was the highest since our series began on Aug 12, 2024. When the S&P 500 rose or fell 1%, United Therapeutics Corporation moved 0.21% on average in the same direction (past 252 trading days). The correlation of 0.08, however, shows only a moderate link to the broad market. Accordingly, moves in the S&P 500 explain only a small part of the daily price moves of United Therapeutics Corporation.
What United Therapeutics Corporation Correlates With
| Instrument | r | −1 … +1 |
|---|---|---|
| MOVR | +0.57 | |
| Accenture Plc Class A | +0.33 | |
| Neurocrine Biosciences Inc. | +0.31 | |
| Roivant Sciences Ltd. | +0.30 | |
| GLMR | +0.26 | |
| Autodesk Inc. | +0.25 | |
| Banco Bilbao Vizcaya Argentaria S.A. | -0.31 | |
| Deere | -0.29 | |
| SAPIEN | -0.28 |
The strongest co-movers are listed at the top, the strongest inverse movers at the bottom. Low or negative correlations can help spread risk more broadly across a portfolio.
